MoonLake Immunotherapeutics
MLTX
MLTX
136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 31 increasing their positions, 43 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
136
Holders Change
+21
Holders Change %
+18.26%
% of All Funds
1.85%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
37
Increased
31
Reduced
43
Closed
15
Calls
$21.1M
Puts
$8.78M
Net Calls
+$12.3M
Net Calls Change
+$9.63M
Top Buyers
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.7M |
| 2 |
Millennium Management
New York
|
+$13.5M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$11.6M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$7.81M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.48M |
Top Sellers
| 1 |
Holocene Advisors
New York
|
-$54.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$44.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$27.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$23.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$18M |
